用于治疗晚期前列腺癌的基于前列腺特异性抗原（PSA）疫苗的开发策略。

Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.

作者信息

Arlen Philip M, Gulley James L, Tsang Kwong-Yok, Schlom Jeffrey

机构信息

Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.

出版信息

Expert Rev Vaccines. 2003 Aug;2(4):483-93. doi: 10.1586/14760584.2.4.483.

DOI:10.1586/14760584.2.4.483

PMID:14711334

Abstract

Prostate cancer is the second leading cause of cancer death in males in the USA. Vaccine strategies represent a novel therapeutic approach. One potential target for a prostate cancer vaccine is prostate-specific antigen (PSA), due to its restricted expression in prostate cancer and normal prostatic epithelial cells. A number of PSAspecific epitopes have been identified that can activate cytotoxic T-lymphocytes (CTLs) and in turn lead to the killing of tumor targets by the peptide-specific CTLs. Strategies have now been employed in clinical trials using RNA-pulsed dendritic cell vaccines, recombinant protein vaccines, and recombinant viral vector delivery of vaccines. Newer approaches incorporating costimulatory molecules that enhance Tcell activation are also being investigated.

摘要

前列腺癌是美国男性癌症死亡的第二大主要原因。疫苗策略代表了一种新型的治疗方法。前列腺癌疫苗的一个潜在靶点是前列腺特异性抗原（PSA），因为它在前列腺癌和正常前列腺上皮细胞中表达受限。已经鉴定出许多PSA特异性表位，它们可以激活细胞毒性T淋巴细胞（CTL），进而导致肽特异性CTL杀死肿瘤靶点。目前，RNA脉冲树突状细胞疫苗、重组蛋白疫苗和重组病毒载体疫苗递送等策略已应用于临床试验。还在研究纳入增强T细胞活化的共刺激分子的更新方法。